All News

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses how compounding pharmacies manage quality assurance when putting together ketamine dosages for patients.

The nasal spray bypasses the gut and potential absorption issues associated with it, and offers consistent relief even when administered hours after the onset of a migraine attack.

New evidence shows that moving to urban areas in the Midwest or either coast could increase the longevity of an individual’s life.

Research shows that individuals who had either a severe or mild case of the virus had an increased risk of kidney damage and disease.

Study shows the benefit of green and blue spaces for individuals with COPD living in urban communities.

As pharmacists were pulled into patient-facing roles, many hospitals were forced to scale back or make adjustments in medication compounding practices.

The guidance noted it is preferable for immunocompromised patients to receive their third dose in a health care delivery setting rather than a pharmacy or public vaccination clinic.

COVID-19 convalescent plasma administered within the first week of symptoms did not prevent disease progression in a high-risk group of outpatients.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

A greater proportion of atogepant-treated participants achieved at least a 50% reduction in mean monthly migraine days.

Study suggests that lack of sleep in the first 6 months following childbirth can add between 3 and 7 years to the mother’s biological age.

Kidney disease is among the most common causes of both hyperkalemia and hypokalemia.

Study indicates that patients with asthma should continue taking their asthma medications during the COVID-19 pandemic.

Alterations in the amino acid profile of children with attention-deficit hyperactivity disorder may support further research into potential new treatment strategies.

The results of a recent Aging-US study show that these additives provide anti-inflammatory and neuroprotective glial subpopulation benefits.

Following a phase 2 study, Moderna submitted initial data to the FDA for the approval of its COVID-19 booster shot that would be administered 6 months after an individual’s second dose.

Calls to poison control centers regarding the use of ivermectin for the prevention or treatment of COVID-19 have increased 5-fold since its baseline before the COVID-19 pandemic.

A study found individuals receiving probiotics had a decrease in C. difficile diagnosed in stool samples than those who did not receive probiotics.

Umeā University in Sweden finds a connection between the two, due to the intestinal micobiome.

Vaccinations are a huge success story in global health care and have helped eliminate smallpox and nearly eradicate polio.

The FDA has approved a second drug, zanubritinib, for the treatment of adult patients with Waldenström’s macroglobulinemia.

In addition to changing the organization's mission and vision, strategic planning actually helps define the business.

Compared to women who followed the Portfolio Diet less frequently, those with the closest alignment were 11% less likely to develop any type of cardiovascular disease, 14% less likely to develop coronary heart disease, and 17% less likely to develop heart failure.

The study authors note that they cannot conclude that there is a causal relationship between the COVID-19 vaccines and any of the individual incidents of Bell palsy reviewed.

AZD7442 reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo.

Inspiratory muscle training was originally devised to be used by athletes and individuals with breathing problems such as chronic obstructive pulmonary disease, asthma, and bronchitis.

Ten quiz questions to assess your knowledge on common treatments for chronic obstructive pulmonary disease.

Lab values for sodium, potassium, chloride, magnesium, BUN, creatinine, glucose, and CO2.

Individuals with COVID-19 were more likely to be asymptomatic if they contracted the virus from a primary case that was also asymptomatic.

Atezolizumab was granted accelerated approval for the mTNBC indication in March 2019, making it the first immunotherapy agent to be approved in this setting.